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19th CardioVascular Summit: TCTAP 2014CYP2C19*2,*3 carriers with cardiovascular diseases and ready to receive PCT are
suggested to pay more attention to stent thrombosis when using clopidogrel. However,
there are differences in cardiovascular and bleeding events between different metab-
olizer of clopidogrel with different CYP2C19*2,*3 Genotype. We surpassed that there
are no statistically signiﬁcant between different metabolizer of Clopidogrel of
bleeding and thrombotic events in acute coronary syndrome patients.
Methods: We enrolled 208 acute coronary syndrome patients from 11/01,2012 to 10/
01,2013, which enrolled in our department of cardiology of Beijing Hospital. All the
patients underwent successful percutaneous coronary drug-eluting stent implantation.
CYP2C19 gene Genotype were detected in all patients, and according to test results
into three groups (Extensive metabolizer, Intermediatemetabolizer, Poor metabolizer).
All candidates were all receiving dual antiplatelet therapy ( clopidogrel 75mg QD plus
aspirin 100mg QD), were given loading dose of clopidogrel 600 mg and aspirin
300mg, All the patients were followed three months and not changed the daily dose of
clopidogrel and aspirin. The cardiovascular endpoints 、stent thrombosis and bleeding
events rates were statisticted by SPSS 16.0.
Results: After taking clopidogrel after stent implantation, cardiovascular event rates
of three groups (Extensive metabolizer, Intermediatemetabolizer, Poor metabolizer)
were 28.6%, 26.0%, 25.0%, P ¼ 0.926; bleeding event rate of three groups were
12.0%, 14.5%, 10%, P ¼ 0.867; thrombotic event rates of three groups were 5.3%,
13.0%, 9.1%, P ¼ 0.256. All clinical endpoint events were not statistically signiﬁcant.
Conclusion: We found that there no statistically signiﬁcant different about clinical
events between three metabolizer type groups. However, because the number of cases
were not large, so itwas early tomake up conclusions that it is not to change the daily dose
of clopidogrel the determined by CYP2C19 gene Genotype. And it need more research.S10 JACC Vol 63/12/Suppl S j April 22–25, 2TCTAP A-035
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Background: Dual antiplatelet therapy (DAPT) for at least 12 months is currently
recommended in all patients with drug-eluting stent (DES) implantation. However,
there are few studies compared between aspirin monotherapy versus clopidogrel
monotherapy after DAPT in patients implanted with DES. We sought to compare the
efﬁcacy and safety of clopidogrel versus aspirin following 12-month of DAPT in
patients undergoing percutaneous coronary intervention (PCI) with DES.
Methods: An observational study was conducted on consecutive patients receiving
DES at Samsung Medical Center in Korea between January 2003 and December 2010.
Landmark analyses were performed among patients who were event-free (no death,
myocardial infarction [MI], revascularization, or cerebrovascular accident [CVA]) at
12-month follow-up. At this point, patients were divided into two groups: aspirin (n ¼
2,477, 76%) versus clopidogrel (n ¼ 784, 24%). Primary outcome was a composite of
cardiac death, MI, or CVA during follow-up. We used weighted Cox proportional
hazards models using inverse-probability-of-treatment weighting.
Results: Clinical, angiographic and procedural characteristics revealed more comor-
bidities and more complex lesions in clopidogrel group compared with aspirin group.
During median follow-up of 59 months, 166 primary composite events were occurred.
In multivariate analysis, clopidogrel was associated with a risk reduction in a com-
posite of cardiac death, MI, or CVA (p ¼ 0.006). A tendency of risk reduction was
also seen in each of cardiac death, MI and CVA.
Conclusion: Following 12-month of DAPT, clopidogrel monotherapy may be asso-
ciated with a risk reduction of recurrent ischemic events compared with aspirin in
patients undergoing PCI with DES.TCTAP A-036
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Background: Studies that compared the reversible P2Y12 inhibitor ticagrelor with the
irreversible inhibitor clopidogrel, dyspnea was observed more frequently with tica-
grelor versus clopidogrel-treated patients (13.8% vs. 7.8%). Out of patients presenting
with dyspnea it was stopped in only less than 1%. How serious is it? How do the
Indian patients respond to it-is not known.
Methods: All the patients who presented in emergency room with diagnosis of
Acute Coronary Syndrome (ACS) and started on ticagrelor along with aspirin as
dual antiplatelet therapy were analysed and prospectively followed for the period of
6 months.
Results: In our experience since October 2012, 166 Acute Coronary Syndrome (ACS)
patients with the mean age of 628years were started on ticagrelor along with aspirin
as dual antiplatelet therapy. Of these 72% were male, 35% had hypertension, 42%
were diabetic, 30% had dyslipidemia and 20% had history of smoking while none of
the patient had bronchial asthma or chronic obstructive airway disease. These patients
were followed up at one week, one month and 6 months. Of 166 patients 31 patients
had complaints of dyspnea 95% of times at one week of follow up. Of all patients
complaining of dyspnea ﬁve presented to the emergency department and were
extensively evaluated to rule out other differentials. Out of 31 patients with dyspnea
20 i.e. 12% of total and 64.5% of patients with dyspnea ticagrelor had to be stopped,
following which patients improved. In the remaining 11 patients dyspnea improved
with time and no patient was discontinued ticagrelor after one month of follow up due
to dyspnea.
Conclusion: Ticagrelor-related dyspnea is more frequent and more severe in intensity
in Indian population as compared to the population reported in PLATO study. It is the
main reason for the discontinuation of ticagrelor in patients of ACS in whom it was
started as a dual antiplatelet regimen.014 j TCTAP Abstracts/ORAL/Antiplatelet Agents and Anticoagulants
